FindTrial
Sign In

Clinical and cardiac imaging in bosentan treatment for pulmonary arterial hypertension

Clinical and cardiac imaging in bosentan treatment for pulmonary arterial hypertension (CMC-PAH study)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0001530
Enrollment
21
Registered
2015-06-22
Start date
2014-12-19
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

The Catholic University of Korea, Seoul St. Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: WHO group 1 pulmonary arterial hypertension (PAH) patients with (1) naive to endothelin receptor blocker (ETRB) patients, or; (2) previous ETRB treatment interrupted >30 days

Exclusion criteria

Exclusion criteria: Patients who cannot 6 minute walk test, contraindication to bosentan, significant arrhythmia impairing adequate ECG-gated cardiac CT imaging, contraindication to CT contrast dye, active malignancy, expected survival <1 year from any cause, failure to obtain informed consent

Design outcomes

Primary

MeasureTime frame
6 minute walk distance—

Secondary

MeasureTime frame
Clinical symptom, laboratory, cardiac CT findings—

Countries

Korea, Republic of

Contacts

Public ContactMi-Jeong Kim

The Catholic University of Korea, Incheon St. Mary's Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026